Search Results

There are 22957 results for: content related to: Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

  1. You have free access to this content
    Clinical Outcomes in Kidney Transplant Recipients Receiving Long-Term Therapy With Inhibitors of the Mammalian Target of Rapamycin

    American Journal of Transplantation

    Volume 12, Issue 2, February 2012, Pages: 379–387, F. Cortazar, M. Z. Molnar, T. Isakova, M. E. Czira, C. P. Kovesdy, D. Roth, I. Mucsi and M. Wolf

    Version of Record online : 4 NOV 2011, DOI: 10.1111/j.1600-6143.2011.03826.x

  2. Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells

    The Prostate

    Volume 75, Issue 7, May 15, 2015, Pages: 693–705, Kiren Yacqub-Usman, Mark R. Pickard and Gwyn T. Williams

    Version of Record online : 3 FEB 2015, DOI: 10.1002/pros.22952

  3. You have free access to this content
    Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

    Transplant International

    Volume 24, Issue 12, December 2011, Pages: 1216–1230, Liset H. M. Pengel, Liang Q. Liu and Peter J. Morris

    Version of Record online : 29 SEP 2011, DOI: 10.1111/j.1432-2277.2011.01357.x

  4. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients

    JDDG: Journal der Deutschen Dermatologischen Gesellschaft

    Volume 12, Issue 6, June 2014, Pages: 480–488, Mareike Alter, Imke Satzger, Harald Schrem, Alexander Kaltenborn, Alexander Kapp and Ralf Gutzmer

    Version of Record online : 12 MAY 2014, DOI: 10.1111/ddg.12355

  5. You have free access to this content
    Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations

    British Journal of Pharmacology

    Volume 171, Issue 16, August 2014, Pages: 3801–3813, M Moschetta, A Reale, C Marasco, A Vacca and M R Carratù

    Version of Record online : 25 JUL 2014, DOI: 10.1111/bph.12749

  6. You have free access to this content
    mTOR inhibition: the learning curve in kidney transplantation

    Transplant International

    Volume 23, Issue 5, May 2010, Pages: 447–460, Matthew R. Weir, Fritz Diekmann, Stuart M. Flechner, Yvon Lebranchu, Didier A. Mandelbrot, Rainer Oberbauer and Barry D. Kahan

    Version of Record online : 3 FEB 2010, DOI: 10.1111/j.1432-2277.2010.01051.x

  7. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation

    The Journal of Clinical Pharmacology

    Volume 55, Issue 4, April 2015, Pages: 368–376, Michael J.G. Somers and Elahna Paul

    Version of Record online : 30 DEC 2014, DOI: 10.1002/jcph.428

  8. You have full text access to this OnlineOpen article
    New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma


    Volume 118, Issue 6, 15 March 2012, Pages: 1486–1497, Mark Agulnik

    Version of Record online : 11 AUG 2011, DOI: 10.1002/cncr.26361

  9. You have free access to this content
    Targeting mTOR in renal cell carcinoma


    Volume 115, Issue S10, 15 May 2009, Pages: 2313–2320, Gary R. Hudes

    Version of Record online : 28 APR 2009, DOI: 10.1002/cncr.24239

  10. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy

    Journal of Cellular Biochemistry

    Volume 114, Issue 6, June 2013, Pages: 1248–1256, Eun Ju Kim, Jae-Hoon Jeong, Sangwoo Bae, Seongman Kang, Cheol Hyeon Kim and Young-Bin Lim

    Version of Record online : 16 APR 2013, DOI: 10.1002/jcb.24465

  11. You have free access to this content
    The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk

    International Journal of Cancer

    Volume 132, Issue 11, 1 June 2013, Pages: 2682–2693, Christian Seitz, Manuela Hugle, Silvia Cristofanon, Aurélie Tchoghandjian and Simone Fulda

    Version of Record online : 4 DEC 2012, DOI: 10.1002/ijc.27935

  12. You have free access to this content
    Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes

    BJU International

    Volume 113, Issue 3, March 2014, Pages: 376–382, Bradley J. Atkinson, Diana H. Cauley, Chaan Ng, Randall E. Millikan, Lianchun Xiao, Paul Corn, Eric Jonasch and Nizar M. Tannir

    Version of Record online : 2 DEC 2013, DOI: 10.1111/bju.12420

  13. You have full text access to this OnlineOpen article
    Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis

    Cancer Medicine

    Volume 2, Issue 6, December 2013, Pages: 862–871, Kenya Yamanaka, Marius Petrulionis, Shibo Lin, Chao Gao, Uwe Galli, Susanne Richter, Susanne Winkler, Philipp Houben, Daniel Schultze, Etsuro Hatano and Peter Schemmer

    Version of Record online : 22 OCT 2013, DOI: 10.1002/cam4.150

  14. You have free access to this content
    Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation

    Liver Transplantation

    Volume 18, Issue 2, February 2012, Pages: 188–194, Roberto Montalti, Antonio Mimmo, Gianluca Rompianesi, Valentina Serra, Nicola Cautero, Roberto Ballarin, Nicola De Ruvo, Robert Cunningham Gerring, Giorgio Enrico Gerunda and Fabrizio Di Benedetto

    Version of Record online : 25 JAN 2012, DOI: 10.1002/lt.22445

  15. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?

    Clinical Transplantation

    Volume 29, Issue 7, July 2015, Pages: 654–663, Mamatha Bhat and Kymberly D. Watt

    Version of Record online : 10 JUN 2015, DOI: 10.1111/ctr.12559

  16. You have free access to this content

    American Journal of Transplantation

    Volume 12, Issue s3, May 2012, Pages: 27–542,

    Version of Record online : 26 APR 2012, DOI: 10.1111/j.1600-6143.2012.04112.x

  17. You have free access to this content
    Finding a better drug for epilepsy: The mTOR pathway as an antiepileptogenic target


    Volume 53, Issue 7, July 2012, Pages: 1119–1130, Aristea S. Galanopoulou, Jan A. Gorter and Carlos Cepeda

    Version of Record online : 11 MAY 2012, DOI: 10.1111/j.1528-1167.2012.03506.x

  18. You have full text access to this Open Access content
    Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer

    Cancer Science

    Volume 100, Issue 12, December 2009, Pages: 2402–2410, Taro Matsuzaki, Masakazu Yashiro, Ryoji Kaizaki, Koichi Yasuda, Yosuke Doi, Tetsuji Sawada, Masaichi Ohira and Kosei Hirakawa

    Version of Record online : 18 AUG 2009, DOI: 10.1111/j.1349-7006.2009.01315.x

  19. You have free access to this content
    mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused

    IUBMB Life

    Volume 63, Issue 10, October 2011, Pages: 896–914, Ismael Bracho-Valdés, Paola Moreno-Alvarez, Israel Valencia-Martínez, Evelyn Robles-Molina, Lydia Chávez-Vargas and José Vázquez-Prado

    Version of Record online : 9 SEP 2011, DOI: 10.1002/iub.558

  20. mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis


    Volume 61, Issue 3, March 2013, Pages: 301–311, Cinzia Dello Russo, Lucia Lisi, Douglas L. Feinstein and Pierluigi Navarra

    Version of Record online : 8 OCT 2012, DOI: 10.1002/glia.22433